Dr. Martens (DOCS) Q3 2026 TU earnings summary

Executive summary

• Strategic pivot underway to drive sustained, profitable growth with a consumer-first approach, disciplined promotions, and optimized distribution.

• On track to deliver all four strategic objectives for FY26, including new market entries, reducing discounted pairs, growing new product families, and simplifying operations.

• Significant profit growth expected for FY26, with strong performance in Americas and broad-based wholesale growth.

• Q3 showed progress, with Americas growth accelerating nearly 20 percentage points on a two-year stack, driven by both retail and wholesale.

• EMEA faced a challenging consumer environment, impacting DTC, but overall pairs sold were slightly up and bags/accessories grew.

Financial highlights

• Q3 Group revenue down 2.7% constant currency (CC) to £253m; YTD Group revenue down 0.7% CC to £580m.

• Q3 wholesale revenue up 9.5% CC; YTD wholesale revenue up 4.2% CC.

• Q3 DTC revenue down 6.5% CC; YTD DTC revenue down 3.3% CC.

• Performing in line with plans on revenue quality, profit before tax, and cash.

• Full price DTC revenues up 2% YTD, especially strong in Americas.

Outlook and guidance

• FY26 revenue expected to be broadly flat on a constant currency basis, with focus on revenue quality and profitability.

• Significant year-on-year PBT growth anticipated, supported by healthy margins and strong cost control.

• Confident in order book health for upcoming seasons, with inventories significantly down and a broader product assortment.

• Early days for U.S. price increases to offset tariffs, with no negative consumer reaction observed so far.

• Currency headwind to Group revenue now expected at £15m, with a broadly neutral impact on Adjusted PBT.